Quick Facts
Plain-English Summary
Mechano Growth Factor is an alternatively spliced isoform of IGF-1 (the Ec variant) produced in skeletal muscle in response to mechanical stretch and damage. Unlike systemic IGF-1 (which signals via the liver), MGF is thought to act locally at sites of muscle stress to activate satellite cells — the muscle stem cells responsible for repairing damaged fibers and contributing nuclei for fiber hypertrophy.
The E-domain peptide — the 24 C-terminal amino acids of MGF — appears to have distinct bioactivity from the IGF-1 domain. In vitro, it stimulates satellite cell proliferation and delays differentiation, maintaining the proliferative pool. In rodent muscle injury models, local MGF injection accelerated satellite cell activation and improved recovery metrics. However, these are largely acute injury studies, not hypertrophy studies.
PEGylation was applied to address MGF's extremely short in vivo half-life. By conjugating polyethylene glycol chains, the plasma half-life extends from ~5 minutes to ~48–72 hours, potentially allowing twice-weekly injection rather than daily. Whether this extended half-life translates to better satellite cell activation — which may be optimally stimulated by acute local peaks rather than sustained levels — is unknown.
No human clinical trial data exists for PEG-MGF. All efficacy data is from rodent muscle injury or in vitro satellite cell studies. The compound is WADA-prohibited (IGF-1 analogues/fragments). Bodybuilding use relies entirely on the theoretical translation of rodent muscle biology to trained human athletes — a translation with no validation.
PEG-MGF purity verification is uniquely difficult. PEGylation quality varies dramatically between manufacturers, and most consumer-grade peptide testing cannot verify the PEG attachment. Users may be injecting unmodified MGF (5-minute half-life, essentially inactive by the time it reaches target tissue) or degraded product. Additionally, the WADA prohibition means competitive athletes risk anti-doping rule violations.
Mechanism of Action
Proposed mechanisms below are derived from in vitro and rodent studies only. No mechanistic pathway has been validated in a controlled human study.
All mechanistic data is derived from in vitro or rodent studies. Applicability of these pathways in humans is not established.
Animal Data
| Model | Finding | ICPS Status |
|---|---|---|
| Rat — muscle injury (cardiotoxin) | Local MGF E-peptide injection (250 mcg) accelerated satellite cell activation and increased muscle fiber cross-sectional area at 14 days post-injury vs controls. Dluzniewska et al. 2005 ↗ | Preclinical |
| Mouse — hindlimb unloading (atrophy model) | MGF administration reduced muscle mass loss during 2 weeks of hindlimb suspension; satellite cell number maintained above unloaded controls. | Preclinical |
| In vitro — human satellite cells | MGF E-domain peptide (10–100 nM) increased satellite cell proliferative index and delayed myogenic differentiation in culture. PMID 21354439 ↗ | Preclinical |
No finding from this section has been replicated in a controlled human trial. Animal-to-human translation for peptides is uncertain and cannot be assumed.
Human Trials
| Trial | Population | Status | ICPS Status |
|---|---|---|---|
| No human trials | — | — | No Data |
| WADA prohibited | All competitive athletes | — | Prohibited |
PEG-MGF has no FDA, EMA, or Health Canada–approved indications and no published Phase III trial data for any condition as of 2026.
Safety & Side Effects
No formal human safety assessment exists. Rodent studies showed no overt toxicity at studied doses. The PEGylation adds a theoretical concern: anti-PEG antibodies can develop with repeated PEGylated protein/peptide exposure, potentially reducing efficacy and causing hypersensitivity reactions — a well-characterized phenomenon with PEGylated therapeutics.
Long-term safety unknown. IGF-1 pathway stimulation carries the same theoretical malignancy promotion concern as all IGF-1-related compounds. PEG immunogenicity with repeated dosing is an uncharacterized risk with the specific PEGylation chemistry used in research peptide products.
- Injection site reactions (redness, swelling)
- Anti-PEG antibody development (theoretical — may reduce efficacy with repeated use)
- Potential IGF-1 pathway-related effects (insulin resistance, soft tissue)
- Unknown — no systematic AE data
- Active or suspected malignancy
- Diabetes or insulin resistance
- Competitive athletics (WADA prohibited)
- Pregnancy or breastfeeding
- Children and adolescents
PEG-MGF is not approved by the FDA, EMA, or Health Canada for any medical indication. It is classified as a research compound and is not legal for human therapeutic use in most jurisdictions. Procurement and use outside of registered clinical trials carries regulatory and unknown health risks.
References
Research disclaimer. CompoundProfile publishes summaries of available scientific literature for educational purposes only. This page does not constitute medical advice and should not be interpreted as an endorsement of PEG-MGF for any therapeutic use. Consult a licensed healthcare professional before considering any research compound. All evidence gradings reflect the state of published literature as of August 2026 and are assessed independently by ICPS.
Community Commentary
Selected discussion from r/Peptides · Curated for signal, not volume
I've used PEG-MGF for 4 cycles. Recovery subjectively is better but I also eat better and sleep better when I'm in that mindset. The site injection for local growth thing — I inject into my lagging body parts. Any visible difference? Maybe. Could be training. Hard to isolate.
PEG-MGF + IGF-1 LR3 is a common stack. The logic is: PEG-MGF activates satellite cells first (proliferation), then IGF-1 LR3 drives differentiation and protein synthesis. No human data supports this sequencing theory but it's common in bodybuilding forums.
Reminder that every IGF-1 fragment/analogue is WADA prohibited. PEG-MGF is explicitly on the prohibited list. If you test positive, 'I didn't know' isn't a defense.
Got my PEG-MGF tested by a peptide testing lab. They couldn't verify the PEGylation — their method doesn't detect it. I have no idea if the product is actually PEGylated. The half-life extension is the whole point of PEG-MGF vs regular MGF and I can't confirm I'm getting it.